, /PRNewswire/ -- Soligenix, Inc. (Nasdaq: ) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to participate in the upcoming Annual Meeting of Stockholders to be held virtually at on . "This Annual Meeting is exceedingly important to the Company," stated , PhD, President and Chief Executive Officer of Soligenix.
"We have a number of proposals to be voted on in order to continue to provide value to our stockholders and advance our rare disease pipeline forward, including our confirmatory Phase 3 study with HyBryte for the treatment of cutaneous T-cell lymphoma (CTCL)." Only stockholders at the close of business on the record date, , will be eligible to participate. Even stockholders as of who have subsequently sold their shares are eligible and encouraged to vote.
While voting via the Internet and by phone before the meeting will be open until at , we encourage eligible stockholders to vote as early as possible to ensure their vote is counted. Eligible stockholders may vote their shares via the Internet, telephone or mail: Please refer to the official proxy filing for further details on each proposal, this can be found at . Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Our Specialized BioTherapeut.